Navigation Links
Prometheus Announces New Chief Medical Officer
Date:11/14/2011

SAN DIEGO, Nov. 14, 2011 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the appointment of Dr. Peter Heseltine as Senior Vice President and Chief Medical Officer.

Dr. Heseltine joins Prometheus with almost 35 years of experience in the medical field.  He comes most recently from Beckman Coulter where he served as Vice President and Medical Director of Global Businesses since 2005. In this role he had corporate responsibility for medical input and oversight of in vitro diagnostics product design, development and life cycle management, including new cancer diagnostics, using immunoassay, flow cytometry and molecular technologies.

Prior to joining Beckman Coulter, Dr. Heseltine was Medical Director of Infectious Diseases at Nichols Institute Quest Diagnostics supervising high-volume, Molecular, Microbiology, Virology and Serology clinical laboratories. He formed a team of research scientists to develop new esoteric tests for infectious diseases under ISO 9001 standards and led a Six Sigma quality improvement program that introduced more than 50 new tests in four years.  Prior to joining Quest Diagnostics, Dr. Heseltine was a Chief Physician at Los Angeles County USC Hospital  and Professor of Medicine at the University of Southern California.  Dr. Heseltine received his medical training at Trinity College, Dublin University and postgraduate training at Yale University, the University of California, Los Angeles and the U. S. Centers for Disease Control. He is Board certified in Internal Medicine and Infectious Diseases. Dr. Heseltine is a Fellow of the American College of Physicians, Fellow of the National Academy of Clinical Biochemistry and a Fellow of the Infectious Diseases Society of America. He maintains a position as Clinical Professor of Medicine at the University of California, Irvine.

"Peter brings a wealth of medical, clinical and product development experience which will be very valuable during this important stage of our company's growth," said Joseph M. Limber, President and Chief Executive Officer of Prometheus. "He is a welcome addition to our senior management team and will play a key role in planning and executing our core strategy as we continue to build on our success."

About Prometheus

Prometheus Laboratories Inc. is committed to improving lives through the development and commercialization of novel pharmaceutical and diagnostic products that enable physicians to provide greater individualized patient care. Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and is applying these principles to oncology. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary diagnostic testing services. By integrating therapeutics and diagnostics, Prometheus believes it can provide physicians with more targeted solutions to optimize care for their patients. Prometheus became part of Nestle Health Science in July 2011.  Prometheus' corporate offices are located in San Diego, California. For more information about Prometheus, please visit www.prometheuslabs.com.

About Nestle Health Science

Nestle Health Science, a fully-owned subsidiary of Nestle S.A., is operational since January 1, 2011 and has worldwide headquarters in Lutry, Switzerland. Nestle Health Science offers nutritional solutions for people with specific dietary needs related to illnesses, disease states or the special challenges of different life stages. For more information about Nestle Health Science, please visit www.nestlehealthscience.com.


'/>"/>
SOURCE Prometheus Laboratories Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
2. Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
3. Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW
4. Prometheus Launches ProOnc Dx Cancer Diagnostics
5. Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S.
6. Prometheus Announces New Method for Real-Time Monitoring of Patients Treated With Biologic Therapy
7. Prometheus and Bayer HealthCare Enter into Services Agreement to Conduct Mutational Analysis
8. Prometheus Highlights Record Performance in 2010
9. Prometheus Obtains Exclusive US Commercialization Rights for RENCAREX®
10. Prometheus Announces Agreement to be Acquired by Nestle Health Science
11. Prometheus and the Medco Research Institute® to Evaluate the Use of Prometheus Thiopurine Metabolite Testing for Optimizing Treatment of Inflammatory Bowel Disease Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... -- Entscheidung fällt als Reaktion ... Die internationale humanitäre Stadt soll um knapp 2800 m² erweitert ... Seine Hoheit Scheich Muhammad bin Raschid Al ... Dubai , hat den Auftrag erteilt, ... City IHC) zu verdreifachen, um den Betrieb zur Unterstützung ...
(Date:1/19/2017)... -- Report Details What can be expected ... to grow at the fastest rates? This visiongain report ... opportunities and prospects. Our 190-page report provides 124 ... in the industry and the future market prospects. Our ... all the major categories of the ophthalmic devices market. ...
(Date:1/19/2017)... Jan. 19, 2017 Report Details ... Alzheimer,s ... Leading Companies – our new study reveals trends, R&D ... and events affecting the Alzheimer,s disease therapeutics and diagnostics ... these key questions: - How is the Alzheimer,s disease ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... January 21, 2017 , ... Phytocéane invites ... isolated from the rest of the world with ZANZIBAR SHOWER GEL. Inspired by the ... key ingredients, Virgin Coconut Oil and moisturizing vegetal coral to create this gentle, crystal-clear ...
(Date:1/21/2017)... ... 21, 2017 , ... The Nobel Biocare™ dental implant company ... for its creos™ line of bone regenerative products. Specifically, the Nobel ... utilizes creos™ allo.gain™ bone graft for a variety of bone reconstruction procedures. In ...
(Date:1/20/2017)... ... January 20, 2017 , ... Doctor C LLC, a ... the January ECRM trade show to continue the marketing and distribution of its product, ... known for providing 400 percent better absorption than traditional vitamin C supplements. At the ...
(Date:1/20/2017)... ... January 20, 2017 , ... Michael and Betsy Brauser celebrated 5 years of ... the clinical trial has been life-saving as she has been on the trial ... Brauser was diagnosed with ovarian cancer in 2009. She underwent standard chemotherapy but a ...
(Date:1/20/2017)... ... ... Chocolate Biscuit”: a biographical account following a man who went on to support his country ... Ivey, born in Lynn Haven, Florida and at the age of 5, his family moved ... he joined the Navy and got married right out of boot camp. , He ...
Breaking Medicine News(10 mins):